A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia

Clinical Therapeutics

Volumn 21, Issue 3, 1999, Pages 536-562

  Hilleman, Daniel E ^a,c   Phillips, Jeffrey O ^b   Mohiuddin, Syed M ^a   Ryschon, Kay L ^a   Pedersen, Craig A ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Missouri   (United States)

^c CREIGHTON UNIVERSITY   (United States)

Author keywords

HMG CoA reductase inhibitor; Hypercholesterolemia; Meta analysis; Pharmacoeconomics

Indexed keywords

ATORVASTATIN; COLESTIPOL; COLESTYRAMINE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0032894878     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88308-3     Document Type: Article

References (114)

1. 1. Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit. Circulation. 1998;97:946-952.
2. 2. Gotto AM. Lipid lowering, regression, and coronary events. A review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, 7th Council Meeting. Circulation. 1995;92:646-656.
3. 3. Holme I. Cholesterol reduction and its impact on coronary artery disease and total mortality. Am J Cardiol. 1995;76(Suppl): 10C-17C.
4. 4. Canner P, Berge K, Wenger N, et al. Fifteen year mortality in coronary drug project patients: Long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
5. 5. Rossouw J, Lewis B, Rifkind B.The value of lowering cholesterol after myocardial infarction. NEJM. 1990;323:1112-1119.
6. 6. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984:251:351-364.
7. 7. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
8. 8. Frick M, Elo O, Haapa K, et al. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. JAMA. 1987;317:1237-1245.
9. 9. Pedersen T, Kjekshus J, Berg K. Randomized trial of cholesterol-lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:383-389.
10. 10. Sacks F, Pfeffer M, Moye L, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. NEJM. 1996;335:1001-1009.
11. 11. Shepherd J, Cobbe S, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. NEJM. 1995;333:1301-1307.
12. 12. National Cholesterol Education Program. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
13. 13. American College of Physicians. Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults. Ann Intern Med. 1996;124:315-517.
14. 14. LaRosa J. Cholesterol agonistics. Ann Intern Med. 1996;124:505-508.
15. 15. Epstein R, Garrahan S, Nelsen L, et al. The cholesterol population model: US population requirements for treatment of hypercholesterolemia. Am J Managed Care. 1996;2:1362-1370,
16. 16. Marceilno J, Feingold K. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med. 1996; 100:605-610.
17. 17. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals. Am J Med. 1996;100:197-204.
18. 18. Schectman G, Hiatt J. Dose-response characteristics of cholesterol-lowering drug therapies: Implications for treatment. Ann Intern Med. 1996;125:990-1000.
19. 19. Reckless J. Cost-effectiveness of hypolipidaemic drugs. Postgrad Med J. 1993;69 (Suppl):S30-S33.
20. 20. Johannesson M, Borgquist L, Nilsson-Ehle P. The cost of screening for hypercholesterolaemia - results from a clinical trial in Swedish primary health care. Scand J Clin Lab Invest. 1993;53:725-732.
21. 21. Field K, Thorogood M, Silagy C. Strategics for reducing coronary risk factors in primary care: Which is most cost effective? BMJ. 1995;310:1109-1112.
22. 22. Kuntz K, Lee T. Cost effectiveness of accepted measures for intervention in coronary heart disease. Coron Artery Dis. 1995;6:472-478.
23. 23. Hunninghake D, Stein E, Dujovne C. The efficacy of dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. NEJM. 1993;328: 1269-1271.
24. 24. Caggiula A, Watson J, Kuller L. Cholesterol-lowering intervention program: Effect of the Step I diet in community practice. Arch Intern Med. 1996;156:1205-1213.
25. 25. Johnson C, Rifkind B, Sempos C. Declining serum total cholesterol levels among US adults: The National Health and Nutrition Examination Surveys. JAMA. 1993;769:3002-3008.
26. 26. Rubins H, Rubins S, Collins D. Distribution of lipids in 8500 men with coronary artery disease. Department of Veterans Affairs HDI. Intervention Trial Study Group. Am J Cardiol. 1995;75:1196-1201.
27. 27. Huedebert G, Van Ruiswky J, Hiatt J, Schectman G. Combination drug therapy for hypercholesterolemia. The trade-off between cost and simplicity. Arch Intern Med. 1993;153:1828-1837.
28. 28. Oster G, Borok G, Menzin J. Cholesterol-Reduction Intervention Study: A randomized trial to assess effectiveness and costs in clinical practice. Arch Intern Med. 1996;156:731-739.
29. 29. Price-Chek PC™ Average Wholesale Prices. Version 2.16. St. Louis, Mo: MediSpan, Inc; 1998.
30. 30. Jones P, Kafonek S, Laurora I, Hunninghake D, for the CURVES Investigators. Comparative dose efficacy of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiol. 1998;81:582-587.
31. 31. Bradford R, Shear C, Chremos A, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) Study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991;151:43-49.
32. 32. Hunninghake D, Knopp R, Schonfeld G, et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study. Atherosclerosis. 1990;85:81-89.
33. 33. Hunninghake D, Mellies M, Goldberg A, et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. A dose-response study. Atherosclerosis. 1990;85:219-227.
34. 34. Vega G, Krauss R, Grundy S. Pravastatin therapy in primary moderate hypercholesterolemia: Changes in metabolism of apolipoprotcin B-containing lipoproteins. J Intern Med. 1990;227:81-94.
35. 35. Saito Y, Goto Y, Nakaya N, et al. Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test. Atherosclerosis. 1988;72:205-211.
36. 36. Capurso A, Resta F, Bertolini S, et al. Lipid control with low-dosage simvastatin in patients with moderate hypercholesterolemia. An Italian multicentre double-blind placebo-controlled study. Eur Heart J. 1992;13:11-16.
37. 37. McDowell I, Smye M, Trinick T, et al. Simvastatin in severe hypercholesterolemia: A placebo controlled trial. Br J Clin Pharmacol. 1991;31:340-343.
38. 38. Peters T, Mehra M, Muratti E. Efficacy and safety of fluvastatin in hypertensive patients. An analysis of a clinical trial database. Am J Hypertens. 1993;6(Suppl): 240S-345S.
39. 39. The Lovastatin Pravastatin Study Group. A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia, Am J Cardiol. 1993;71:810-815.
40. 40. McPherson R, Bedard J, Connelly P, et al. Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia. Clin Ther. 1992;14:276-291.
41. 41. Ditschuneit H, Kuhn K, Ditschuneit H. Comparison of different HMG-CoA reductase inhibitors. Eur J Clin Pharmacol. 1991;40(Suppl):S27-S32.
42. 42. Farmer J, Washington L, Jones P, et al. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. Clin Ther. 1992;14:708-717.
43. 43. Malini P, Ambrosioni E, De Divitiis O, et al. Simvastatin versus pravastatin: Efficacy and tolerability in patients with primary hypercholesterolemia. Clin Ther. 1991;13:500-510.
44. 44. The Simvastatin Pravaslatin Study Group. Comparison of the efficacy, safely and tolerability of simvastatin and pravastatin for hypercholesterolemia. Am J Cardiol. 1993;71:1408-1414.
45. 45. The European Study Group. Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia (multicountry comparative study). Am J Cardiol. 1992;70:1281-1286.
46. 46. Yoshino G, Kazumi T, Matsushila M, et al. Comparison of the effects of pravastatin and simvastatin in hypercholesterolemic subjects. Curr Ther Res. 1990; 48:259-267.
47. 47. Lintott C, Scott R, Sutherland W, Bremer J. Treating hypercholesterolemia with HMG-CoA reductase inhibitors: A direct comparison of simvastatin and pravastatin. Aust New Zealand J Med. 1993;23: 381-386.
48. 48. Stalenhoef A, Lansberg P, Kroon A, et al. Treatment of primary hypercholesterolemia. Short-term efficacy and safely of increasing doses of simvastatin and pravaslatin: A double-blind comparative study. J Intern Med. 1993;234:77-82.
49. 49. Simvastatin-Pravastatin European Study Group. Sinhagen-Thiessen E. Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Cardiology. 1994;85:244-254.
50. 50. Martens L, Rutten F, Erkelens B, Ascoop C. Cost effectiveness of cholesterol-lowering therapy in Netherlands: Simvastatin versus cholestyramine. Am J Med. 1989; 87:545-585.
51. 51. Martens L, Rutten F, Erkelens D, Ascoop C. Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: The case of simvastatin and cholestyramine in the Netherlands. Am J Cardiol. 1990; 65:27F-32F.
52. 52. Schulman K, Kinosian B, Jacobson T. Reducing high blood cholesterol level with drugs: Cost-effectiveness of pharmacologic management. JAMA. 1990;264:3025-3033.
53. 53. Goldman L, Weinstein M, Goldman P, Williams L, Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA. 1991;265:1145-1151.
54. 54. Hay J, Wittels E, Gott A. An economic evaluation of lovastalin for cholesterol lowering and coronary artery disease. Am J Cardiol. 1991:67:789-796.
55. 55. Hjalte K, Lindgren B, Persson U. Cost-effectiveness of simvastalin versus cholestyramine: Results from Sweden. Pharmaco-Economics. 1992;1:213-216.
56. 56. Lim M, Foo WM. Efficacy and cost-effectiveness of simvastatin and gemfibrozil in the treatment of hyperlipidemia. Ann Acad Med Singapore. 1992;21:34-37.
57. 57. Guibert R, Contandriopoulos A, Champagne F. Cost-effectiveness analysis of lipid modulators in Canada. Results and potential usefulness. Can J Cardiol. 1993; 9(Suppl):28D-29D.
58. 58. Goldman L, Goldman P, Williams L. Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications. Am J Cardiol. 1993;72(Suppl):75D-79D.
59. 59. Martens L, Guibert R. Cost-effectiveness analysis of lipid-modifying therapy in Canada: Comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Clin Ther. 1994;16:1052-1062.
60. 60. Smart A, Walters L. Pharmacoeconomic assessment of the HMG-CoA reductase inhibitors. S Afr Med J. 1994;84:834-837.
61. 61. Hamilton V, Racicot F, Zowell H. The cost-effectiveness of HMG-CoA reductase inhibitors: Estimating the benefits of increasing HDL-C. JAMA. 1995;273:1032-1038.
62. 62. Korman K, Borysiuk L. Replacing lovastatin with pravastatin: Effect on serum lipids and costs. Am J Health-Syst Pharm. 1995;52:1078-1082.
63. 63. Pedersen T, Kjekshus J, Berg K. Cholesterol lowering and the use of health resources. Results of the Scandinavian Simvastatin Survival Study. Circulation. 1996; 93:1796-1802.
64. 64. Ooi T, Heinonen T, Aleupovic P. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: Comparison with fenofibrate. Arterioscler Thromb Vasc Biol. 1997;12:33-37.
65. 65. Davidson M, McKenney J, Stein E. Long-term efficacy and safety of atorvastatin compared to lovastatin in hypercholesterolemic patients. Am J Cardiol. 1997; 79:1475-1481.
66. 66. Dart A, Jerums G, Nicholson G. A multicenter, double-blind, 1 year study comparing the safety and efficacy of once daily atorvastatin with that of simvastatin in patients with hypercholesterolemia. Am J Cardiol. 1997;80:39-44.
67. 67. Bertolini S, Bittolo-Bon G, Campbell L. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis. 1997; 130:191-197.
68. 68. Sirtori C, Arca M, Barone A, et al. Clinical evaluation of simvastatin in patients with severe hypercholesterolemia. Curr Ther Res. 1989;46:230-239.
69. 69. Stein E, Kreisberg R, Miller V, et al. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Arch Intern Med. 1990; 150:341-345.
70. 70. Simons L. Simvastatin in severe primary hypercholesterolemia: Efficacy, safety and tolerability in 595 patients over 18 weeks. Clin Cardiol. 1993;16:317-322.
71. 71. Davidson M, Stein E, Dujovne C, et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol. 1997;79:38-42.
72. 72. Bard J, Dallongeville J, Hagen E, et al. Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition. Metabolism. 1995;44:1447-1454.
73. 73. Pravastatin Multicenter Study Group II. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Arch Intern Med. 1993:153:1321-1329.
74. 74. Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med. 1993;94:13-20.
75. 75. Davidson M. Fluvastatin long-term extension trial (FLUENT): Summary of efficacy and safety. Am J Med. 1994;96 (Suppl):41S-44S.
76. 76. Dallongeville J, Fruchart J, Pfister P, Bard J. Fluvastalin reduces levels of plasma Apo B-containing particles and increases those of LpA-1. Am J Med. 1994;96 (Suppl):32S-36S.
77. 77. Jacotot B, Banga J, Pfister P, Mehra M. Efficacy of a low dose-range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients. Br J Clin Pharmacol. 1994;38:257-263.
78. 78. Jacotot B, Benghozi R, Pfister P, Holmes D. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. Am J Cardiol. 1995;76:54A-56A.
79. 79. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol. 1993;72:1031-1037.
80. 80. Prisant L, Downton M, Walkins L, et al. Efficacy and tolerability of lovastatin in 459 African-Americans with hypercholesterolemia. Am J Cardiol. 1996;78:420-424.
81. 81. The Lovastatin Study Group III. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. JAMA. 1998;260: 359-366.
82. 82. Hunninghake D, Stein E, Dujovne C, et al. The efficacy of intensive dietary therapy alone or combined with lovastatin in out-patients with hypercholesterolemia. NEJM. 1993;328:1213-1219.
83. 83. Illingworth D, Stein E, Knopp R, et al. A randomized multicenter trial comparing the efficacy of simvastatin and fluvastatin. J Cardiovasc Pharmacol Ther. 1990;1:23-30.
84. 84. Tikkanen M, Bocanegra T, Walker J, Cook T. Comparison of low-dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol. Am J Med. 1989;87(Suppl):47S-53S.
85. 85. Brown B, Sacco D, Zhao X, et al. Triple therapy (niacin, lovastatin, colestipol) for lipid lowering in coronary disease. Does it enhance the benefits associated with prior double therapy? Circulation. 1992;86 (Suppl 1):1-716. Abstract.
86. 86. Davidson M, Schwartz S, Fletcher G, et al. Efficacy of combination cholestyramine and lovastatin therapy for the treatment of hypercholesterolemia. J Am Coll Cardiol. 1991;17:188A. Abstract.
87. 87. Davignon J, Roederer G, Montigny M, et al. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol. 1994;73:339-345.
88. 88. Erkelens D, Baggen M, Van Dormaal J. Clinical experience with simvastatin compared with cholestyramine. Drugs. 1988; 36:87-92.
89. 89. Hagen E, Istad H, Ose L, et al. Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine. Eur J Clin Pharmacol. 1994;46:445-449.
90. 90. Hoogerbrugge N, Mol M, Van Dormaal J, et al. The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia. J Intern Med. 1990; 228:261-266.
91. 91. Jacobson TA, Chin MM, Fromell GJ, et al. Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol. 1994; 74:149-154.
92. 92. Jacotot B, Banga J, Waite R, Peters T. Long-term efficacy with fluvastatin as monotherapy and combined with cholestyramine (a 156 week multicenter study). Am J Cardiol. 1995;76:41A-46A.
93. 93. Leren T, Hjermann I, Foss O, et al. Long-term effect of lovastatin alone and in combination with cholestyramine on lipoprotein(a) level in familial hypercholesterolemic subjects. Clin Invest. 1992;70:711-718.
94. 94. O'Brien R, Simons L, Clifton P, et al. Comparison of simvastatin and cholestyramine in the treatment of primary hypercholesterolaemia. Med J Aust. 1990;152:480-483.
95. 95. Ojala J, Helve E, Karjalainen K, et al. Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: A 3-year follow-up. Atherosclerosis. 1990; 82:85-95.
96. 96. Malloy M, Kane J, Kunitake S, Tun P. Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia. Ann Intern Med. 1987;107:616-623.
97. 97. Sasaki J, Yamamoto K, Kobori S, et al. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients. Int J Clin Pharmacol Ther. 1995;33:420-426.
98. 98. Simons L, Simons J, Parfitt A. Successful management of primary hypercholesterolaemia with simvastatin and low-dose colestipol. Med J Aust. 1992; 157:455-458.
99. 99. Sprecher D, Abrams J, Allen J, et al. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidernic patients. Ann Intern Med. 1994;120:537-543.
100. 100. Stein E, Lamkin G, Bewley D. Lovastatin alone and in combination for treatment of primary hypercholesterolemia. Prog Clin Biol Res. 1988;225;281-293.
101. 101. Tsalamandris C, Panagiotopoulos S, Sinha A, et al. Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients. J Cardiovasc Risk. 1994;1:231-239.
102. 102. Uusitupa M, Eberling T, Happonen P, et al. Combination therapy with lovastatin and guar gum versus lovastatin and cholestyramine in treatment of hypercholesterolemia. J Cardiovasc Pharmacol. 1991:18:496-503.
103. 103. Vacek JL, Dittmeier D, Chiarelli T, White J, et al. Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia. Am J Cardiol. 1995;76:182-184.
104. 104. Wilson M. Implementation of guidelines in a managed care setting. Am J Managed Care. 1996;2:538-541.
105. 105. McKenney J. The lipid-lowering formulary. Am J Managed Care. 1996;2:548-553.
106. 106. Illingworth D, Tobert J. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther. 1994;16:366-385.
107. 107. Kong S, Gandhi S, Crawford S, Serger J. Pharmacoeconomic evaluation of HMG-CoA reductase inhibitors in the treatment of hypercholesterolemia. Am J Managed Care. 1996;2:1055-1073.
108. 108. Cucherat M, Boissel J. Meta-analysis of results from clinical trials on prevention of coronary heart disease by lipid-lowering interventions. Clin Trials Meta-anal. 1993; 38:109-129.
109. 109. Holme I. Relation of coronary heart disease incidence and total mortality to plasma cholesterol reduction in randomized trials: Use of meta-analysis. Br Heart J. 1993:69:542-547.
110. 110. Zocor® [package insert]. West Point, Pa: Merck & Co., Inc.; 1996.
111. 111. Lipitor™ [package insert]. Morris Plains, NJ: Parke-Davis; 1996.
112. 112. Lescol® [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 1996.
113. 113. Mevacor® [package insert]. West Point, Pa: Merck & Company, Inc.; 1996.
114. 114. Pravachol® [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 1995.